Virtus Biotech Clinical Trials ETF

BBC

Market cap $43M

Investors are questioning the staying power of medical technology (medtech) stocks, which have fallen from grace since the COVID-19 pandemic. The starting point is to distinguish between medtech and other healthcare industries.

After a 50%+ run from lows last April through highs in mid-January, the Biotech group has been trending sideways over the last few months. Biotech hasn't garnered much attention lately, with all the coverage of the Iran War and the AI Doom trade that's been taking down software stocks even as AI infrastructure stocks continue to surge.

Biotech ETF BBC hits a 52-week high, likely fueled by strong clinical trial results and rising M&A activity, and renewed risk-on sentiment.

Wall Street put up a modest show in the final quarter of 2025, with the S&P 500 advancing only 1.9%, the Dow Jones gaining 3.3% and the Nasdaq Composite adding about 2.1%. The small-cap index Russell 2000 added 1.6% during that period.

Biotech ETF BBC hits a 52-week high amid renewed sector momentum, Fed rate cuts and AI-driven healthcare gains, hinting at more near-term upside.

Healthcare and biotech led last week's winners, with EPHE, BBC, HELX, XHS and SURI topping ETF gains as markets slid on AI worries and Fed uncertainty.

Top ETFs that soared last week despite market swings included shipping (BWET), lithium miners (LITP), crypto bear (REKT), biotech (BBC) and rare earths (REMX).

The healthcare sector has experienced one of its most significant de-ratings in 35 years, with valuations now at a 30% discount to the broader market. Healthcare trades at historical valuation discounts across multiple metrics.

Biotech ETF BBC just hit a 52-week high on regulatory tailwinds, Fed rate-cut hopes, and cheaper valuations.

Trade war jitters rise, but ETFs like MSOS, SILJ, SGDJ, BBC, WISE & CTEX shine on solid fundamentals, offering either safe havens or growth potential.